ArticleHepatic medicine : evidence and research2020
Prospective Comparison of Transient Elastography Using Two Different Devices: Performance of FibroScan and FibroTouch.
Article in Hepatic medicine : evidence and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- The association between atherogenic index of plasma (AIP) and ultrasound attenuation parameter (UAP) in Chinese adults: a cross-sectional study.Scientific reports · 2026Article
- Dual cut-offs and beyond: Expanding the role of transient elastography in primary biliary cholangitis.World journal of gastroenterology · 2026Article
- Diagnostic performance of controlled attenuation parameter for grading hepatic steatosis in MASLD: an MRI-PDFF-referenced study in a Chinese cohort.Frontiers in medicine · 2026Article
- Comparison of two transient elastography (TE) systems for measuring liver stiffness in clinical practice.Scientific reports · 2025Article
- Liver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024Article
- Vibration-controlled Transient Elastography in NAFLD: Review Study.Euroasian journal of hepato-gastroenterology · 2022Review
- NAFLD: Mechanisms, Treatments, and Biomarkers.Biomolecules · 2022Review
- Article
- Non-alcoholic fatty liver diseases: current challenges and future directions.Annals of translational medicine · 2021Review
- Comparison of Visual Transient Elastography and Shear Wave Elastography in Evaluating Liver Fibrosis in Patients with Chronic Liver Disease.International journal of general medicine · 2021Article
- The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature.Obesity surgery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransient elastography (TE) using FibroScan (FS) has been established to non-invasively assess liver fibrosis and steatosis. The aim of this study was to compare the recently introduced FibroTouch (FT) device with the established FS with respect to liver stiffness and CAP. PATIENTS AND
methodsThirty-nine patients with and without liver disease were included. All patients were measured three times with FS (FibroScan 530 compact, Echosens, France) and FT (FibroTouch-FT100, Wuxi Hisky Med, China). For FS, M and XL probe were used according to the manufacturer's specifications. For steatosis, CAP and the comparable FT equivalent UAP (ultrasound attenuation parameter) was determined. Finally, FT and FS were explored in liver tissue-mimicking phantoms.
resultsLS between FS and FT correlated well with r=0.91. Root-mean-square (RMS) of the coefficient of variation for LS was better in FS (11.1% vs 27.4%). Bland-Altman analysis showed a 3.1 kPa mean overestimation of LS by FT. In addition, UAP strongly and linearly depended on the BMI following UAP=3.02 × BMI+186. In phantoms, a similar relation was found with UAP (phantom)= 3.78 × BMI + 146 suggesting that UAP is directly calculated from entered BMI instead of assessing shear-wave attenuation. Consequently, RMS-CV was lower for FT (6.0% vs 9.7%). However, if using different BMI, CV-RMS for FT increased to 12.7%. LS of a patient with manifest liver cirrhosis and ascites was 38.8 kPa using the FS-XL probe but almost normal with FT (7.2 kPa).
conclusionAlthough LS by FT shows good correlation with LS-FS, it has larger variation, continuously overestimates LS and completely fails in ascites. Moreover, FT-UAP seems to be a misleading parameter for steatosis assessment because it is at least in part calculated from mandatory entered patient data. In conclusion, novel LS cut-off values need to be defined for LS-FT and usage of UAP is not recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.